Page 53 - EJMO-9-1

Eurasian Journal of Medicine and
Oncology
BRCA VUS in breast cancer in MENA region

cisplatin. Cancer Res. 2016;76(9):2778-2790. synonymous mutations in cancer. In: Sauna ZE, Kimchi-
Sarfaty C, editors. Single Nucleotide Polymorphisms: Human
doi: 10.1158/0008-5472.CAN-16-0186
Variation and a Coming Revolution in Biology and Medicine.
58. Labidi-Galy SI, Rodrigues M, Sandoval JL, et al. Berlin: Springer International Publishing; 2022. p. 77-96.
Association of location of BRCA1 and BRCA2 mutations doi: 10.1007/978-3-031-05616-1_5
with benefit from olaparib and bevacizumab maintenance
in high-grade ovarian cancer: Phase III PAOLA-1/ 62. Kim JH, Park S, Park HS, et al. Analysis of BRCA1/2
ENGOT-ov25 trial subgroup exploratory analysis. Ann variants of unknown significance in the prospective Korean
Oncol. 2023;34(2):152-162. Hereditary Breast Cancer study. Sci Rep. 2021;11(1):8485.
doi: 10.1016/j.annonc.2022.11.003 doi: 10.1038/s41598-021-87792-w
59. Vreeswijk MPG, Kraan JN, van der Klift HM, et al. Intronic 63. Macklin S, Durand N, Atwal P, Hines S. Observed frequency
variants in BRCA1 and BRCA2 that affect RNA splicing can and challenges of variant reclassification in a hereditary
be reliably selected by splice-site prediction programs. Hum cancer clinic. Genet Med. 2018;20(3):346-350.
Mutat. 2009;30(1):107-114. doi: 10.1038/gim.2017.207
doi: 10.1002/humu.20811 64. Al-Jumaan M, Chu H, Alsulaiman A, et al. Interplay of
60. Caputo SM, Golmard L, Léone M, et al. Classification of Mendelian and polygenic risk factors in Arab breast cancer
101 BRCA1 and BRCA2 variants of uncertain significance patients. Genome Med. 2023;15(1):65.
by cosegregation study: A powerful approach. Am J Hum doi: 10.1186/s13073-023-01220-4
Genet. 2021;108(10):1907-1923.
65. Alper Gezdirici EGİ. Hereditary breast-ovarian cancer and
doi: 10.1016/j.ajhg.2021.09.003 BRCA1/BRCA2 variants: A single center experience. Acta
Haematol Oncol Turc. 2021;54(3):264-272.
61. Herreros E, Janssens X, Pepe D, Keersmaecker KD. SNPs
ability to influence disease risk: Breaking the silence on doi: 10.5505/aot.2021.25348

Volume 9 Issue 1 (2025) 45 doi: 10.36922/ejmo.5800